ReviewClinical journal of oncology nursing2026
Beefing Up Awareness: Navigating Alpha-Gal Syndrome.
Review in Clinical journal of oncology nursing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evolution of alpha-Gal synthesis - a growing risk for alpha Gal syndrome.Annals of medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundAlpha-gal syndrome (AGS) is an acquired allergy caused by an immunoglobulin E-mediated reaction to alpha-gal, or galactose-alpha-1,3-galactose, a sugar molecule found in mammalian meat. Clinicians can increase awareness of AGS because many medications, including oncologic treatments, contain animal products.
objectivesThis article provides foundational knowledge on AGS, emerging treatment options, and the impact of this allergy on oncologic treatment.
methodsCurrent evidence on the incidence, epidemiology, diagnosis, and management of AGS in oncology care is summarized, with a focus on nursing implications.
findingsAGS is a growing concern for oncology providers. Education for patients and staff allows for effective management of patients with AGS. Patients need to avoid mammalian meat and most dairy products, as well as products and medications that contain alpha-gal or mammalian protein-derived additives, and report any allergy symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.